摘要
目的:探讨核酪口服液联合孟鲁司特钠对哮喘患儿炎性水平及气道功能的影响。方法:2019-03~2020-07我院收治的91例哮喘患儿的临床资料,将应用孟鲁司特钠治疗的43例患儿纳入对照组,将应用核酪口服液+孟鲁司特钠治疗的48例患儿纳入观察组。分别比较两组治疗前及治疗1个月后的炎性因子[白细胞介素(IL)-17、IL-8]水平及气道功能[气道峰压(PIP)、气道阻力(Raw)]。结果:治疗1个月后,两组IL-17、IL-8水平均较治疗前降低,且观察组各指标水平低于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组PIP、Raw均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:对哮喘患儿应用核酪口服液联合孟鲁司特钠治疗可有效改善炎症反应,促进患儿气道功能恢复。
Objective:To investigate the effect of Niftyros oral liquid combined with montelukast sodium on inflammatory level and airway function in children with asthma.Methods:The clinical data of 91 children with asthma treated in our hospital from March 2019 to July 2020 were analyzed retrospectively,The control group included 43 children treated with montelukast sodium,48 children treated with montelukast sodium were included in the observation group.The levels of inflammatory factors[interleukin(IL)-17,IL-8]and airway function[airway peak pressure(PIP),airway resistance(Raw)]were compared between the two groups before and after treatment for 1 month.Results:1 month after treatment,Both groups had lower IL-17、IL-8 levels than before,And the index level of the observation group was lower than that of the control group,difference was statistically significant(P<0.05);After 1 month of treatment,Both groups had lower PIP、Raw than before,And the observation group was lower than the control group,difference was statistically significant(P<0.05).Conclusion:The treatment of children with asthmatic asthma with Niftyros oral liquid combined with montelukast sodium can effectively improve the inflammatory response,Promote the recovery of airway function in children.
作者
席磊
XI Lei(First People's Hospital of Nanyang,Henan,Nanyang 473000,China)
出处
《黑龙江医药科学》
2022年第2期75-76,共2页
Heilongjiang Medicine and Pharmacy
关键词
哮喘
核酪口服液
孟鲁司特钠
炎症反应
气道功能
asthma
Nino-tyros oral liquid
montelukast sodium
inflammatory response
airway function
